European Federation of Biotechnology and Elsevier Announce Launch of Biotechnology Journal
New journal to focus on original research, opinions and political understanding of biotechnology
Amsterdam, 5 February 2007 – Elsevier will launch Biotechnology, the Journal, as the official publication of the European Federation of Biotechnology (EFB) in September 2007. Biotechnology, the Journal will be a cross-disciplinary research and review journal aimed at an audience of academic and commercial bioscientists who are interested not only in science but also in its translation and use. The bi-monthly journal will be a platform for peer-reviewed articles and editorial comments related to biotechnology.
Editor-in-Chief of the journal will be John Hodgson who was Editor of Trends in Biotechnology and Senior Editor of Nature Biotechnology. Hodgson is one of the founders of the biotech consultancy firm, Critical I. According to Hodgson, Biotechnology, the Journal will have a global reach in content and subscription base. "It is important for the credibility of Biotechnology, the Journal that it publishes the best in science and reflects technical and political discussion in an entirely international context. The journal will be inclusive, reaching eastward and westward, seeking the excitement and opportunity in the sciences, technologies and businesses behind biotechnology".
The launch of this exciting journal is planned to coincide with the start of ECB13, The European Congress on Biotechnology, which will be held from September 16th – 19th in Barcelona, Spain. EFB Secretary General Christian Suojanen comments, "We are extremely pleased to be able to launch the journal with both John Hodgson and Elsevier as partners. Biotechnology, the Journal, will seek to reflect the EFB’s recognition that the boundaries of science and commerce do not stop at the borders of the European Union, and that it is vital that Biotechnology, the Journal provides the global context that our members need. We firmly believe that the journal will be a success and thus aid in serving both our members and the life sciences community as a whole".
# # #
About the European Federation of Biotechnology
Established by European scientists in 1978, the European Federation of Biotechnology (EFB) is Europe’s non-profit federation of National Biotechnology Associations, Learned Societies, Universities, Scientific Institutes, Biotech Companies and Individuals, with 225 Institutional Members and 5,000 personal members in 56 countries working to promote biotechnology throughout Europe and beyond.
The mission of EFB is to advance the sustainable and beneficial use of the life sciences, to promote research and innovation at the cutting edge of biotechnology, to provide a forum for interdisciplinary and international cooperation, to improve scientific education and to facilitate an informed dialogue between scientists and the public.
The EFB has 13 Regional Branch Offices across Europe, one in Beijing and another in development in Moscow. The Central Office is located in Barcelona, Spain. www.efb-central.org
Every two years the EFB organizes the European Congress on Biotechnology. The 13th edition takes place in Barcelona 16-19 September 2007. www.ecb13.eu
About Elsevier Society Publishing
Elsevier is committed to building unique, long-lasting relationships to help societies achieve their publishing goals and provide value-added member services. Elsevier partners with more than 500 international learned societies, professional associations and research institutes. To learn more, please visit the Society homepage on Elsevier.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com